Overview

This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.

Eligibility

Inclusion Criteria:

• Aged between 20 and 60 (male or female)
• Diagnosed chronic decompensated hepatitis B cirrhosis with a course of more than 5 years
• Not suitable for liver transplantation or there is no donor liver source
• No serious bleeding tendency or active bleeding
• No hepatic encephalopathy
• After strict medical conservative treatment for more than 6 months, there was no relief of symptoms or significant improvement of quality of life score
• Subjects voluntarily participate in this study and sign informed consent

Exclusion Criteria:

• Be less than 20 years old or more than 60 years old
• Cirrhosis caused by other causes such as alcoholic hepatitis, hepatitis C virus and autoimmune hepatitis
• Found liver malignant tumor or the family history of liver malignant tumor in the third generation of their direct relatives
• Patients with hypersplenism who need splenectomy
• History of tumors in other organs
• PT prolongation is greater than 3 seconds
• Use of human serum albumin within 3 weeks prior to clinical registration
• Clinically significant upper gastrointestinal bleeding events occurred within 4 weeks before clinical registration
• Spontaneous peritonitis
• Active infection (viral or bacterial)
• Pregnant or lactating women
• The researcher considers it inappropriate to participate in this study